5 results match your criteria: "Groupe Hospitalier HUPC[Affiliation]"
The rising challenge of oncogene addiction in lung cancer.
Bull Cancer
June 2021
Hôpital Cochin, Groupe Hospitalier HUPC, Department of Pneumology, Thoracic Oncology Unit, AP-HP, 27, rue du Faubourg Saint-Jacques, Paris, France. Electronic address:
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by Mutation Subtypes.
JTO Clin Res Rep
September 2020
Department of Pneumology, Thoracic Oncology Unit, AP-HP, Groupe Hospitalier HUPC, Hôpital Cochin, Paris, France.
Introduction: mutations are detected in 20% to 30% of NSCLC. However, mutation subtypes may differently influence the outcome of patients with advanced NSCLC.
Methods: In the Biomarkers France study, 4894 mutations (26.
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
J Thorac Oncol
May 2020
Department of Thoracic Oncology, AP-HP, Groupe Hospitalier HUPC, Hôpital Cochin, Paris, France; Centre de Recherche des Cordeliers, Université Paris Descartes, Complement, Inflammation and Cancer, Paris, France. Electronic address:
Introduction: Immune checkpoint inhibitors (ICIs) have improved cancer prognosis but have not been evaluated specifically in sarcomatoid carcinoma (SC), a rare lung cancer subtype with poor prognosis. As such, our study sought to retrospectively assess the efficacy of ICI in SC.
Methods: All consecutive patients with centrally confirmed SC treated using ICI as a second-line treatment or beyond between 2011 and 2017 were enrolled.
Novel ADGRG2 truncating variants in patients with X-linked congenital absence of vas deferens.
Andrology
May 2020
Service de Génétique Médicale, Centre Hospitalier Universitaire, Toulouse, France.
Article Synopsis
- - The study investigates the role of the ADGRG2 gene in congenital absence of vas deferens (CAVD), finding that mutations in this gene are significant in cases where no or only one CFTR gene mutation is present.
- - Researchers sequenced the ADGRG2 gene in 53 patients with various CFTR mutation statuses, discovering six new truncating mutations linked to CAVD.
- - They found a 26% mutation frequency in patients with confirmed kidney functionality, indicating that ADGRG2 mutations could frequently occur alongside CFTR mutations but are likely to be the primary cause of CAVD in these cases.
Transthyretin for the routine assessment of malnutrition: A clinical dilemma highlighted by an international survey of experts in the field.
Clin Nutr
December 2018
Service de Biochimie, Hôpital Cochin, Groupe Hospitalier HUPC, APHP, Paris, France; Laboratoire de biologie de la Nutrition EA4466 PRETRAM, Université Paris Descartes, Paris, France. Electronic address:
The value of transthyretin (TTR) measurement for assessing malnutrition is under debate due to its sensitivity to inflammation and frequent confusion over its meaning (i.e. as a marker of diagnosis, prognosis, or efficacy of refeeding).
View Article and Find Full Text PDF